Accurexa and StemImmune have entered a co-development agreement to develop stem-cell-mediated immunotherapy for cancer.
Pursuant to the agreement, Accurexa’s targeted therapies delivering will be combined with StemImmune’s immunotherapy for the treatment of cancer by delivering anti-cancer payload to the tumour cells.
The agreement enables the partners to develop novel therapies to treat brain cancer.
Perlara PBC has entered a drug discovery and development partnership with Novartis to further expand its drug discovery platform technology and discovery programmes.
Pursuant to the agreement, the two partners will identify and develop new therapeutics for lysosomal storage disorders, starting with Niemann-Pick type C disease.
The agreement enables Perlara to develop therapeutics to treat patients with lysosomal storage disorders.
Myovant Sciences plans to raise $195 million through the initial public offering (IPO) of 13 million common stock shares.
Conyers Dill & Pearman is acting as the legal advisor for the offering.
The company plans to use the funds to further advance the phase III clinical programmes for relugolix and clinical trials for RVT-602 and also for acquisition or in-license of complementary products.
ADC Therapeutics has raised $105 million through the private placement of its shares.
The company plans to invest the funds in order to advance the clinical development of its pipeline, as well as for commercial manufacturing of its lead programmes.
Science 37 has raised $31 million through a series B venturing financing round led by Redmile Group LLC and co-led by Lux Capital Management, dRx Capital and Sanofi Genzyme BioVentures.
The company plans to invest the proceeds for expansion of its operations and development of its technology platform into new therapeutic areas.